510(k) Report

FDA product code · Immunology

System, Test, Tumor Marker, For Detection Of Bladder Cancer

NAHClass IIIPMA required1 decision since 19960 recalls

1 FDA decision since 1996. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, immunology panel

Twenty years of NAH at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · NAH

1in 2022

2008: 22011: 12012: 22013: 22015: 12016: 22017: 22018: 22019: 12021: 12022: 1
2007high 2 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NAH

Too few NAH 510(k)s in any year since 2007 to give a median.

Recalls per year · NAH

No recall names NAH since 2007.

Adverse event reports per year · NAH

1in 2021

2021: 1
2007high 1 (2021) · low 0 (2007)2025

MAUDE reports naming product code NAH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20082—00
20090—00
20100—00
20111—00
20122—00
20132—00
20140—00
20151—00
20162—00
20172—00
20182—00
20191—00
20200—00
20211—01
20221—00
20230—00
20240—00
20250—00
20260—0—
FIG. 1 — NAH by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in NAH? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report